ArticleMolecular medicine (Cambridge, Mass.)2025
Androgens alleviate the depression-like phenotype in female mice by inhibiting AVPR1a in the hippocampal brain region.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening of antidepressant effective active components ofFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe prevalence of depression in women is approximately twice that in men. Differences in androgens levels between men and women, due to gonadal differences, may be associated with the development of depression, although the underlying mechanisms are not well understood.
methodsWe evaluated the depressive phenotypes of female mice following low-dose androgen treatment using a variety of behavioral and in vivo electrophysiological experiments. The mRNA profile of hippocampal tissues from female mice treated with dehydroepiandrosterone (DHEA) was constructed through RNA sequencing (RNA-seq). GO and KEGG pathway analyses were performed on the differentially expressed genes. The expression changes of candidate differential genes were verified in hippocampal tissues by quantitative real-time PCR and western blotting. Moreover, the mechanism of action of the DHEA-regulated differential gene (Avpr1a), which is involved in the neuroactive ligand-receptor interaction pathway, was determined in vitro.
resultsChronic DHEA treatment resulted in a distinct antidepressant phenotype and significantly enhanced neuronal excitability of the ventral hippocampal region of female mice. RNA-seq identified the crucial differentially expressed gene, Avpr1a. In vitro experiments showed that DHEA reduced levels of the AVP system. Additionally, ChIP-PCR experiments revealed that Avpr1a directly targets androgen receptor (AR). Cell function experiments demonstrated that DHEA can inhibit AVPR1a expression through AR in a dose-dependent manner, and this effect can be reversed by the androgen receptor antagonist (Flutamide).
conclusionAndrogens (DHEA) exert antidepressant effects by inhibiting the binding of Avpr1a to AR. The Avpr1a gene may serve as a new target for the treatment of depression in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.